Business Palatin reports US$13.2m in fiscal 2026 licence revenue, flags near‑term MC4R study starts Rajesh Pillay · September 28, 2026
Business Orchestra BioMed says BACKBEAT trial on track, R110m cash gives runway into late 2027 Rajesh Pillay · August 11, 2026
Business Biohaven advances first extracellular degraders, phases in pivotal trials and Regeneron pact Rajesh Pillay · August 10, 2026
Business
